Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02353312 · ClinicalTrials.gov registry record · NA
Rhode Island Diastolic Dysfunction - Heart Failure
A NA study, sponsored by Providence VA Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT02353312 is a NA study that has completed, run by Providence VA Medical Center. The registered enrollment target is 28 participants.
The verdict
NCT02353312, a NA study, has completed, sponsored by Providence VA Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
To study the hypothesis that treating patients with underlying diastolic dysfunction with oral Kuvan® (BH4, also known as tetrahydrobiopterin) in addition to current best practices will improve metabolic and echocardiographic diastolic function parameters.
Interventions
- DRUG Kuvan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02353312
The ClinicalTrials.gov registry entry for NCT02353312 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence VA Medical Center, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Kuvan is the first listed.
NCT02353312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02353312 about?
NCT02353312 is a clinical study titled "Rhode Island Diastolic Dysfunction - Heart Failure". To study the hypothesis that treating patients with underlying diastolic dysfunction with oral Kuvan® (BH4, also known as tetrahydrobiopterin) in addition to current best practices will improve metabolic and echocardiographic diastolic function parameters.
What is the current status of trial NCT02353312?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2015-03. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02353312?
The interventions under investigation include: Kuvan (DRUG).
Who is sponsoring clinical trial NCT02353312?
This trial is sponsored by Providence VA Medical Center, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.